Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1328

1.
2.

Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update.

Pham T, Fautrel B, Dernis E, Goupille P, Guillemin F, Le Loët X, Ravaud P, Claudepierre P, Miceli-Richard C, de Bandt M, Breban M, Maillefert JF, Masson C, Saraux A, Schaeverbeke T, Wendling D, Mariette X, Combe B; Club Rhumatismes et Inflammation (CRI/SFR)..

Joint Bone Spine. 2007 Dec;74(6):638-46. Epub 2007 Nov 8.

PMID:
18065252
3.

GISEA: an Italian biological agents registry in rheumatology.

Lapadula G, Ferraccioli G, Ferri C, Punzi L, Trotta F; GISEA..

Reumatismo. 2011 Nov 9;63(3):155-64. doi: 10.4081/reumatismo.2011.155.

PMID:
22257916
4.

Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment.

Alivernini S, Mazzotta D, Zoli A, Ferraccioli G.

Drugs Aging. 2009;26(5):395-402. doi: 10.2165/00002512-200926050-00003.

PMID:
19552491
5.
7.

Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.

Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.

Curr Med Res Opin. 2006 Jan;22(1):169-83.

PMID:
16393443
8.

Assessing remission in clinical practice.

Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS.

Rheumatology (Oxford). 2007 Jun;46(6):975-9. Epub 2007 Mar 6.

PMID:
17341506
9.

Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis.

Fautrel B, Constantin A, Morel J, Vittecoq O, Cantagrel A, Combe B, Dougados M, Le Loët X, Mariette X, Pham T, Puéchal X, Sibilia J, Soubrier M, Ravaud P; Rheumatism and Inflammation Club (CRI) and of the French Society for Rheumatology..

Joint Bone Spine. 2006 Jul;73(4):433-41. Epub 2006 Jun 5.

PMID:
16798046
10.

Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years' drug survival.

Levälampi T, Korpela M, Vuolteenaho K, Moilanen E.

Rheumatol Int. 2010 Nov;30(12):1611-20. doi: 10.1007/s00296-009-1203-1. Epub 2009 Oct 10.

PMID:
19820942
11.

Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.

Horák P, Skácelová M, Hejduk K, Smržová A, Pavelka K.

Clin Rheumatol. 2013 Oct;32(10):1451-8. doi: 10.1007/s10067-013-2303-6. Epub 2013 Jun 2.

PMID:
23728498
12.

Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic.

Duftner C, Dejaco C, Larcher H, Schirmer M, Herold M.

Rheumatol Int. 2008 Nov;29(1):69-73. doi: 10.1007/s00296-008-0621-9. Epub 2008 May 27. Erratum in: Rheumatol Int. 2008 Nov;29(1):75.

PMID:
18504584
13.

Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.

Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J.

Ann Rheum Dis. 2008 Mar;67(3):340-5. Epub 2007 Oct 29.

14.

Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.

Cantini F, Niccoli L, Nannini C, Cassarà E, Pasquetti P, Olivieri I, Salvarani C.

Rheumatology (Oxford). 2008 Jun;47(6):872-6. doi: 10.1093/rheumatology/ken059. Epub 2008 Apr 9.

PMID:
18400836
15.

Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment.

Levälampi T, Korpela M, Vuolteenaho K, Moilanen E.

Scand J Rheumatol. 2008 Jan-Feb;37(1):6-12. doi: 10.1080/03009740701633337.

PMID:
18189188
16.

Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis.

Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K.

Arthritis Rheum. 2007 Aug 15;57(6):935-42.

17.

Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.

Lyu R, Govoni M, Ding Q, Black CM, Kachroo S, Fan T, Ogbonnaya A, Donga P, Hill J, Makin C.

Rheumatol Int. 2016 Jan;36(1):143-53. doi: 10.1007/s00296-015-3348-4. Epub 2015 Aug 28.

PMID:
26314368
18.

Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study.

Konttinen L, Kankaanpää E, Luosujärvi R, Blåfield H, Vuori K, Hakala M, Rantalaiho V, Savolainen E, Uutela T, Nordström D; ROB-FIN Study Group..

Clin Rheumatol. 2006 Nov;25(6):882-4. Epub 2006 Mar 22.

PMID:
16552464
19.

Prescription rheumatology practices among Mexican specialists.

Goycochea-Robles MV, Arce-Salinas CA, Guzmán-Vázquez S, Cardiel-Ríos MH.

Arch Med Res. 2007 Apr;38(3):354-9.

PMID:
17350489
20.

Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases.

Kádár G, Balázs E, Soós B, Laduver A, Keszthelyi P, Szekanecz Z, Kovács L.

Clin Rheumatol. 2014 Mar;33(3):329-33. doi: 10.1007/s10067-014-2508-3. Epub 2014 Feb 5.

PMID:
24497172

Supplemental Content

Support Center